OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report
Shimpei Eguchi, Hiroji Shinkawa, Yasunori Sato, et al.
Clinical Journal of Gastroenterology (2021) Vol. 14, Iss. 3, pp. 858-865
Closed Access | Times Cited: 7
Shimpei Eguchi, Hiroji Shinkawa, Yasunori Sato, et al.
Clinical Journal of Gastroenterology (2021) Vol. 14, Iss. 3, pp. 858-865
Closed Access | Times Cited: 7
Showing 7 citing articles:
Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer
Maria S. Asdourian, Nishi Shah, Ted V. Jacoby, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 8, pp. 933-933
Closed Access | Times Cited: 39
Maria S. Asdourian, Nishi Shah, Ted V. Jacoby, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 8, pp. 933-933
Closed Access | Times Cited: 39
Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid
Jianglin Wang, Xin Hu, Wei Jiang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 9
Jianglin Wang, Xin Hu, Wei Jiang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 9
Late‑onset immune checkpoint inhibitor‑related pneumonitis after cessation of sintilimab: A case report and literature review
Yupei Wu, Yuesong Yin, Xiaolu Yan, et al.
Experimental and Therapeutic Medicine (2023) Vol. 25, Iss. 2
Open Access | Times Cited: 5
Yupei Wu, Yuesong Yin, Xiaolu Yan, et al.
Experimental and Therapeutic Medicine (2023) Vol. 25, Iss. 2
Open Access | Times Cited: 5
Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinoma
Xinjun Lu, Benjamin L. Green, Changqing Xie, et al.
JHEP Reports (2023) Vol. 5, Iss. 7, pp. 100723-100723
Open Access | Times Cited: 4
Xinjun Lu, Benjamin L. Green, Changqing Xie, et al.
JHEP Reports (2023) Vol. 5, Iss. 7, pp. 100723-100723
Open Access | Times Cited: 4
Immunotherapeutic strategies in hepatopancreatobiliary cancers
Massimiliano Salati, Alessandro Rizzo, Angela Dalia Ricci, et al.
Elsevier eBooks (2024), pp. 103-124
Closed Access
Massimiliano Salati, Alessandro Rizzo, Angela Dalia Ricci, et al.
Elsevier eBooks (2024), pp. 103-124
Closed Access
Durable response after the discontinuation of pembrolizumab treatment due to an adverse event in a patient with advanced endometrial cancer: A case report
Shuntaro Umihira, Takahiro Koyanagi, Kohei Tamura, et al.
Experimental and Therapeutic Medicine (2022) Vol. 23, Iss. 6
Open Access | Times Cited: 2
Shuntaro Umihira, Takahiro Koyanagi, Kohei Tamura, et al.
Experimental and Therapeutic Medicine (2022) Vol. 23, Iss. 6
Open Access | Times Cited: 2
A case of unresectable locally advanced intrahepatic cholangiocarcinoma that achieved pathological complete response after gemcitabine and S1 chemotherapy
Tatsuaki Sumiyoshi, Kenichiro Uemura, Ryuta Shintakuya, et al.
Clinical Journal of Gastroenterology (2022) Vol. 15, Iss. 6, pp. 1164-1168
Closed Access | Times Cited: 1
Tatsuaki Sumiyoshi, Kenichiro Uemura, Ryuta Shintakuya, et al.
Clinical Journal of Gastroenterology (2022) Vol. 15, Iss. 6, pp. 1164-1168
Closed Access | Times Cited: 1
